Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Infliximab & Crohn's Disease (CD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Infliximab (Remicade TM and biosimilars) is approved by both the FDA and EMA for the treatment of Crohn's disease (CD) in adult and pediatric patients.
Kornbluth 1998 Inflammatory Bowel Diseases 4(4): 328-329

Patients with Crohn's disease (CD) after Infliximab treatment displayed an increased diversity and richness, a significant gain in SCFAs-producing bacteria, and a loss of [pathogenic bacteria](brain://aKAC0T2fKU6Ss8xccKia4A/Path…

References (Sources)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Reinisch et al. 2021 Inflammatory Bowel Diseases 27(1): 106-122
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Ye et al. 2019 Lancet 393: 1699-1707
Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease
Zhuang et al. 2020 Inflamm Bowel Dis 26: 1636
Infliximab Approved for Use in Crohn's Disease: A Report on the FDA GI Advisory Committee Conference
Kornbluth 1998 Inflammatory Bowel Diseases 4(4): 328-329
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab
Barberio et al. 2020 Inflamm Bowel Dis 26: 756–763
Monocytes from inﬂiximab-resistant patients with Crohn’s disease exhibit a disordered cytokine proﬁle
Gaiani et al. 2020 Sci Rep 10: 12238

AI Chat

7/1/2026

Chat with our artificial intelligence: